EUVIMEDEUVIMED entdecken
Crossref

Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer

Hongxia Xiang, Juan Zhao, Tong Ding, Linjing Zhou, Yunfeng Wang

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04539-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Hongxia Xiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, East Campus of Xinxiang Central Hospital, the northwest corner of, Muye District , Rongxiao East Road and Dongming Avenue, He…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Drug Resistance, Neoplasm, Phytoalexins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medicarpin (Med) is a natural flavonoid extract that has demonstrated promising anti-tumor activity in a variety of cancers. The effect of Med on malignant progression and chemotherapy resistance in breast cancer (BC) is currently unclear. Cisplatin-resistant (CisR) MCF-7 cells were constructed. The effects of different doses of Med and Cisplatin (Cis) on the viability of MCF-7 and CisR-MCF-7 cells were examined through Cell Counting Kit-8 (CCK-8) assay. Biological characterization of BC cells was evaluated by EdU staining, Hoechst 33,258 staining, Transwell assay, flow cytometry, and Scratch-wound assay. Comet assay and immunofluorescence to assess cellular DNA damage. Western blot detected DNA damage-related proteins, apoptosis-related protein, cycle-blocking-related protein, and AKT/Bcl2 pathway protein levels. Additionally, a nude mice subcutaneous graft tumor model was constructed, and the impact of Med on tumor growth was explored by pathological staining. The results showed that Med (80 μM) decreased the viability of both MCF-7 and CisR-MCF-7 cells. Either Med or Cis suppressed cell proliferation, hindered migration and invasion, induced apoptosis, and caused cellular DNA damage and cycle arrest. Med blocked the AKT/Bcl2 pathway. All of the above indices were significantly reversed in BC cells after addition of the AKT agonist SC79. However, the AKT inhibitor MK2206 increased the effect of Med, further inhibited the malignant progression of BC cells, and induced cellular DNA damage and cycle arrest. In addition, injection of either Med or Cis caused a decline in Ki67 positivity and a rise in TUNEL positivity in tumor tissues, which in turn suppressed tumor growth. The effect of the combined treatment of the two was higher than single treatment, indicating that Med could improve the therapeutic efficacy of Cis and reduce the drug resistance of CisR-MCF-7 cells. Med inhibits BC malignant biological behavior and reduces Cis resistance by blocking the AKT/Bcl2 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsDrug Resistance, NeoplasmPhytoalexinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2PterocarpansAnimalsFemaleHumansMiceCisplatinMCF-7 CellsMice, Inbred BALB CMice, NudeDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Breast cancerCisplatin-resistantCycle arrestDNA damageMedicarpin

Substanzen

Antineoplastic AgentsCisplatinmedicarpinPhytoalexinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Pterocarpans

Autor:innen und Institutionen

  • Department of Oncology, East Campus of Xinxiang Central Hospital, the northwest corner of, Muye District , Rongxiao East Road and Dongming Avenue, Henan Province, 453000, China. Xianghx3816@hotmail.com.
  • Department of Orthopedics, Xinxiang Central Hospital, Xinxiang , Henan Province, 453000, China.
  • Department of Oncology, East Campus of Xinxiang Central Hospital, the northwest corner of, Muye District , Rongxiao East Road and Dongming Avenue, Henan Province, 453000, China.

Zitieren

APA

Xiang, H., Zhao, J., Ding, T., Zhou, L., & Wang, Y. (2026). Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04539-4

Vancouver

Xiang H, Zhao J, Ding T, Zhou L, Wang Y. Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04539-4

BibTeX
@article{Xiang2026,
  author = {Xiang, Hongxia and Zhao, Juan and Ding, Tong and Zhou, Linjing and Wang, Yunfeng},
  title = {Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04539-4}
}
Kostenlos starten →